Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2010

01-06-2010 | Gastrointestinal Oncology

In Reply: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must Be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma

Authors: D. Baratti, MD, S. Kusamura, MD, PhD, A. D. Cabras, MD, B. Laterza, MD, M. R. Balestra, MD, M. Deraco, MD

Published in: Annals of Surgical Oncology | Issue 6/2010

Login to get access

Excerpt

We appreciate the interest in our paper of 2 world-recognized experts in peritoneal surface malignancies and local-regional therapies such as Dr. Sugarbaker and Dr. Alexander.1 We agree with Dr. Sugarbaker that the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) should be regarded as the treatment of choice for patients with potentially resectable diffuse malignant peritoneal mesothelioma (DMPM) and good performance status. …
Literature
1.
Alexander RH. Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol. 2010;17:21.CrossRefPubMed
2.
Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D. Malignant peritoneal mesothelioma-results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–8.CrossRefPubMed
3.
Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26:3567–72.CrossRefPubMed
4.
Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol. 1999;6:582–90.CrossRefPubMed
5.
Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587–93.CrossRefPubMed
6.
Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827–34.CrossRefPubMed
7.
Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph-node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010:17:45–53.CrossRefPubMed
8.
Yan TD, Deraco M, Baratti D, Chua T, Elias D, Faheez M, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma—a multi-institutional registry study. J Clin Oncol. 2009;27:6237–42.CrossRefPubMed
9.
Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007;29:453–66.PubMed
10.
Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene. 2007;26:610–7.CrossRefPubMed
11.
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.CrossRefPubMed
Metadata
Title
In Reply: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must Be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma
Authors
D. Baratti, MD
S. Kusamura, MD, PhD
A. D. Cabras, MD
B. Laterza, MD
M. R. Balestra, MD
M. Deraco, MD
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1047-7

Other articles of this Issue 6/2010

Annals of Surgical Oncology 6/2010 Go to the issue

Healthcare Policy and Outcomes

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

Gastrointestinal Oncology

Should Chemoradiotherapy Be Used in Node-Negative Esophageal or Gastric Adenocarcinoma?

Melanomas

2010 TNM Staging System for Cutaneous Melanoma…and Beyond

Hepatobiliary Tumors

Prognostic Significance of c-erbB-2 and Vascular Endothelial Growth Factor in Colorectal Liver Metastases

Gastrointestinal Oncology

Chemoradiotherapy in Adenocarcinoma of the Stomach or Esophagus

Gynecologic Oncology

Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV Disease